Hemispherx Biopharma, Inc. has unveiled a voluntary pay for stock plan (the Plan).
Autor(es):
Resumo: In addition, the CEO/Chairman and President/CFO, will both voluntarily reduce their salaries further to a cumulative reduction of 50%. The plan goes in effect immediately. We are all excited for the opportunity to invest in Hemispherxs future, said Hemispherxs Chairman and CEO, Dr. William A. Carter, Our efforts will be redoubled in 2016 to make progress on all of our major goals. Foremost, in the major goal categories are: a) accelerating success in the recently initiated Expanded Access programs globally for both Ampligen (an experimental therapeutic) and Alferon N; b) achieving further regulatory progress with Ampligen as a potential biotherapeutic for Chronic Fatigue Syndrome (CFS) treatment; c) advancing new clinical tests in cancer immunotherapy, including potential treatment of metastatic colon cancer wherein all standard of care therapies have faltered; and expanding research on the use of our experimental drug Ampligen and Alferon N as an early onset broad spectrum antivirals for diseases such as MERS, Ebola virus, Equine Encephalitis and, given the new pandemic threat, the Zika virus. Previous studies (preclinical) have shown that both Ampligen and interferon are active against the flavivirus family of viruses which includes the West Nile virus and Zika virus. About Hemispherx Biopharma Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherxs flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Alferon LDO.
Palavras-Chave: Biotechnology industry, Planning, Stock prices
Imprenta: Biotech Financial Reports, v. 23, n. 3, 2016.
Descritores: Zika virus - Cell ; Zika virus - RNA ; Zika virus - Infectious diseases ; Zika virus - RNA virus ; Zika virus - Head size
Data de publicação: 2016
